Background-Dabigatran and rivaroxaban are novel oral anticoagulants approved for prevention of venous thromboembolism after hip or knee arthroplasty. However, information assessing clinically important efficacy and bleeding outcomes of these 2 new agents versus low-molecular-weight heparin (enoxaparin) 
V enous thromboembolism (VTE) is a common complication after hip or knee arthroplasty. 1,2 Low-molecularweight heparin reduces the risk of VTE by approximately one half compared with placebo, but it is inconvenient for out-of-hospital use because of the requirement for daily subcutaneous injections. 3 Recent research has focused on the development of new oral anticoagulants that can be administered in fixed dosages with the expectation that they will provide safe and effective alternatives to existing therapies. Two novel agents are the direct thrombin inhibitor dabigatran etexilate (referred to hereafter as dabigatran) and the selective factor Xa inhibitor rivaroxaban, both of which have been approved for use in several countries for prevention of VTE in patients undergoing hip or knee arthroplasty. Enoxaparin was used as the comparator through the development programs of both agents.
With the availability of these new oral anticoagulants, clinicians will need guidance on which one to use. When evaluating an anticoagulant, a reduction in risk of VTE is balanced against a risk of serious bleeding, particularly in joint arthroplasty because bleeding into the replaced joint can have a detrimental effect on the surgical outcome. 4 To evaluate the merits of the new agents, we performed separate pooled analyses of phase III randomized trials that compared enoxaparin versus dabigatran or versus rivaroxaban, assessing clinically important efficacy and bleeding outcomes. In each analysis, we compared trials using equivalent durations of prophylaxis and assessed efficacy and bleeding using similar definitions in all trials.
WHAT IS KNOWN
• Currently available anticoagulants are effective for prophylaxis of venous thromboembolism (VTE) after elective hip or knee arthroplasty, but either requires parenteral administration (eg, enoxaparin) or are difficult to manage because they require laboratory monitoring to adjust the dose (vitamin K antagonists).
• New oral anticoagulants, such as the direct thrombin inhibitor dabigatran and the selective factor Xa inhibitor rivaroxaban, target specific components of the coagulation cascade and can be administered in fixed dosages without laboratory monitoring.
WHAT THE STUDY ADDS
• The study presents separate pooled analyses of efficacy and safety data from 6 phase III randomized trials comparing equivalent durations of treatment with enoxaparin (40 mg once daily or 30 mg twice daily) versus dabigatran (220 mg once daily) or rivaroxaban (10 mg once daily) after elective hip or knee arthroplasty.
• Enoxaparin had similar rates of efficacy and risk of bleeding compared with dabigatran. When compared with rivaroxaban, however, enoxaparin was associated with a significant 2-fold increase in the risk of symptomatic VTE plus all-cause mortality, equivalent to an excess of 6 events per 1000 patients treated; there was also a significantly lower risk of major or clinically relevant nonmajor bleeding, equivalent to 6 fewer events per 1000 patients treated.
• The findings may have important implications for the choice of prophylactic antithrombotic agent in patients undergoing hip or knee arthroplasty.
Methods
A protocol was prospectively developed, detailing the objectives, criteria for study selection, primary and secondary outcomes, and statistical methods. Each study included in this analysis had previously been approved by relevant local research ethics board, and all patients provided informed consent.
Trial Selection
Trial selection was confined to phase III randomized trials that compared equivalent durations of treatment for elective hip arthroplasty or elective knee arthroplasty, respectively, with enoxaparin (40 mg once daily or 30 mg twice daily) versus approved doses of dabigatran (220 mg once daily with a dose of 110 mg on the day of surgery) or versus approved doses of rivaroxaban (10 mg once daily) for the prophylaxis of VTE after elective hip or knee arthroplasty. Although 2 doses of dabigatran (220 and 150 mg once daily) were compared with enoxaparin, we restricted our primary assessment to the approved 220 mg once daily dose. Six randomized trials, involving a combined total of 18 405 patients, were available for inclusion in the separate pooled analyses (8185 comparing enoxaparin versus dabigatran [5] [6] [7] and 10 220 comparing enoxaparin versus rivaroxaban 8 -10 ) (Table) . One trial (REgulation of coagulation in ORthopedic surgery to prevent Deep venous thrombosis and pulmonary embolism [RECORD] 2) did not meet our inclusion criteria 11 because in that study different durations of treatment for rivaroxaban (31 to 39 days) and enoxaparin (10 to 14 days) were compared, and complete data were not available for all of the efficacy and safety end points with equivalent durations of treatment. All 6 trials provided information on the methods used to generate the randomized treatment allocation with adequate concealment of treatment allocation. All studies were double-blind.
Outcomes and Data Extraction
The primary efficacy outcome for each analysis was the composite of symptomatic VTE, which includes deep-vein thrombosis and pulmonary embolism and all-cause mortality during the treatment period. The primary bleeding outcome was the composite of major bleeding (the primary safety end point in each trial) and clinically relevant nonmajor bleeding during treatment, as defined in the individual trials. This bleeding end point definition was used because it was reported in all trials and accounted for differences in the definition of major bleeding used in the 2 trial programs (See supplemental Table 1 ). Secondary outcomes included individual components of the primary efficacy and bleeding outcomes; total VTE and all-cause mortality at end of treatment (the primary end point in each trial); major VTE plus VTE-related mortality at end of treatment; and adverse events during treatment including hepatic enzyme elevations and cardiovascular events. The latter also was assessed in the follow-up periods. Total VTE included symptomatic or asymptomatic deep-vein thrombosis documented by lower-limb venography and nonfatal pulmonary embolism; major VTE included proximal deep-vein thrombosis and nonfatal pulmonary embolism. Two investigators (D.J.Q., S.S.) independently extracted data on study design, study quality, and efficacy and safety outcomes during the treatment period and follow-up periods. We accepted the authors' definitions for clinical outcomes and did not attempt to reclassify them retrospectively. The data abstracted for each trial were confirmed by reviewer consensus and then sent to the first or corresponding author for verification. Missing data were requested from the authors or sponsoring pharmaceutical company or obtained from Sponsor and Regulatory Agency websites. 12, 13 
Statistical Analysis
We used a fixed-effects model based on the Mantel-Haenszel method for combining results from the individual trials. 14 We calculated the odds ratios (OR) and 95% confidence intervals (CI). All statistical calculations were performed using Review Manager (RevMan, version 5.0.18. Copenhagen, The Cochrane Collaboration 2008) and Comprehensive Meta-Analysis (version 2.0, Biostat, Englewood, NJ). Heterogeneity was assessed using Cochran Q and the I 2 statistic: A probability value Ͻ0.10 was considered to denote statistically significant heterogeneity; where I 2 was Ͼ50%, heterogeneity was considered substantial. 15, 16 We removed one study at a time to assess the source of the heterogeneity (where present).
We performed the following subgroup analyses: enoxaparin versus dabigatran 150 mg once daily, which is recommended for specific patient populations, including those patients over 75 years of age or those with moderate renal impairment; and inclusion of primary efficacy and bleeding data comparing equivalent durations of treatment (at 14 days) from the RECORD2 trial 11 in the comparison of enoxaparin versus rivaroxaban. Sensitivity analyses were conducted to further explore the robustness of our results. To identify any study that may have exerted a disproportionate influence on the summary treatment effect, we deleted studies one at a time. We explored the potential for publication bias using funnel plots of effect size versus standard error. 17 We also compared results obtained using a fixed-effects model with those obtained using a randomeffects model.
Results

Enoxaparin Versus Dabigatran (3 Trials, n‫)5818؍‬
Two studies included patients undergoing elective knee arthroplasty 5, 6 and 1 study included patients undergoing elective hip arthroplasty. 7 Enoxaparin was given at a dose of 40 mg once daily starting before surgery in 2 trials 6,7 and 30 mg twice daily starting after surgery in 1 trial. 5 Dabigatran was given at a dose of 150 or 220 mg once daily starting after surgery and continued for 6 to 14 days in the knee arthroplasty studies 5, 6 and for 28 to 35 days in the hip arthroplasty study. 7 Follow-up was 3 months after surgery for all studies. The number of patients lost to follow-up at 3 months was not reported in any of the primary publications, but, based on unpublished data supplied by the sponsor, follow-up was Ͼ99% in all 3 trials.
There was a similar risk of symptomatic VTE plus allcause mortality among patients treated with enoxaparin compared with dabigatran (0.9% versus 1.1%; OR, 0.76; 95% CI, 0.44 to 1.31), but there was significant heterogeneity (Pϭ0.02, I 2 ϭ76%) for this outcome ( Figure 1A ). Statistical heterogeneity was reduced when the RE-MODEL study was removed from the analysis (OR, 0.49; 95% CI, 0.26 to 0.49; P for heterogeneityϭ0.19; I 2 ϭ41%). Secondary efficacy outcomes, including total VTE plus all-cause mortality and major VTE plus VTE-related mortality, showed no significant differences between the 2 treatment groups (heterogeneity tests: Pϭ0.09; I 2 ϭ58% and Pϭ0.22, I 2 ϭ35%, respectively) (data not shown).
The composite of major and clinically relevant nonmajor bleeding was similar in patients treated with enoxaparin versus dabigatran (5.0% versus 5.6%; OR, 0.90; 95% CI, 0.71 to 1.15) without evidence for heterogeneity ( Figure 1B ). The absolute risk of bleeding in each of the 2 treatment groups was lower in the RE-MOBILIZE trial 5 (3.8% for enoxaparin, 3.3% for dabigatran) compared with the RE-NOVATE 7 (5.0% and 6.2%, respectively) and RE-MODEL 6 (6.6% and 7.4%, respectively) trials. Secondary bleeding outcomes, including major bleeding and its individual components, showed no significant differences between the 2 treatment groups ( Figure 2 ). The majority of the major bleeding events were caused by bleeding leading to transfusion of Ն2 U of blood (33 of 39 events with enoxaparin and 33 of 38 events with dabigatran) and bleeding associated with hemoglobin drop of Ն20 g/L compared with prerandomization level (32 of 39 events with enoxaparin and 29 of 38 events with dabigatran).
With the exception of a moderate increase in the concentration of alanine aminotransferase (more than 3 times the upper limit of the normal range) at any time after baseline with enoxaparin (3.6%) compared with dabigatran (2.2%; Pϭ0.003), there were no statistically significant differences between the treatments regarding any safety outcomes, including adverse events leading to discontinuation, cardiovascular events (during treatment or after discontinuation), and wound infections ( Figure 2 ).
Enoxaparin Versus Rivaroxaban (3 Trials; n‫01؍‬ 220)
Two studies included patients undergoing elective knee arthroplasty 9,10 and 1 study included patients undergoing elective hip arthroplasty. 8 Enoxaparin was given at a dose of 40 mg once daily starting before surgery in 2 trials 8, 9 and 30 mg twice daily starting after surgery in 1 trial. 10 Rivaroxaban was given at a dose of 10 mg once daily starting after surgery in all studies and continued for 10 to 15 days in the knee arthroplasty studies 9, 10 and for 28 to 35 days in the hip arthroplasty study. 10 Follow-up ranged from 1.5 to 2 months after surgery for all studies. The number of patients lost to follow-up at 3 months was not reported in any of the primary publications, but, based on data reported by the sponsor in a submission to the regulatory authorities, 13 follow-up was Ͼ99% in all 3 trials.
There was a significant 2-fold higher risk of symptomatic VTE plus all-cause mortality (1.2% versus 0.6%; OR, 2.04; 95% CI, 1.32 to 3.17) among patients treated with enoxaparin compared with rivaroxaban without evidence for heterogeneity ( Figure 3A) . A similar treatment effect was observed for the secondary efficacy outcomes of total VTE plus all-cause mortality and major VTE plus VTE-related mortality (heterogeneity tests: Pϭ0.03; I 2 ϭ72% and Pϭ0.04, I 2 ϭ69%, respectively) (data not shown). Statistical heterogeneity for both of these outcomes was reduced when the RECORD1 study was removed from the analysis (data not shown).
The composite of major and clinically relevant nonmajor bleeding was significantly lower in patients treated with enoxaparin versus rivaroxaban (2.5% versus 3.1%; OR, 0.79; 95% CI, 0.62 to 0.99; Pϭ0.049) without evidence for heterogeneity ( Figure 3B ). Secondary bleeding outcomes, including major bleeding and its individual components, showed similar but nonsignificant differences between the 2 treatment groups (Figure 4) . The majority of the major bleeding events were caused by bleeding leading to reoperation (7 of 12 events with enoxaparin and 12 of 23 events with rivaroxaban). Enoxaparin compared with rivaroxaban was associated with a nonsignificant 75% reduction in a hemoglobin drop of Ն20 g/L compared with postoperative level (0.0% versus 0.1%; OR, 0.25; 95% CI, 0.05 to 1.18) as well as 75% reduction in bleeding associated with transfusion of Ն2 U of whole blood or packed cells (0.0% versus 0.1%; OR, 0.25; 95% CI, 0.05 to 1.18).
Enoxaparin was associated with significant increases in adverse events leading to discontinuation (224 events versus 184 events; Pϭ0.047), reported serious adverse events (397 events versus 316 events; Pϭ0.002), and concentrations of alanine aminotransferase (Ͼ3 times the upper limit of the normal range) at any time after baseline (2.4%) compared with rivaroxaban (1.7%; Pϭ0.02). The higher number of serious adverse events and adverse leading to discontinuation with enoxaparin were mainly due to deep vein thrombosis and pulmonary embolism events. There were no statistically significant differences between the treatments regarding cardiovascular events (during treatment or after discontinuation) or wound infections.
Subgroup and Sensitivity Analyses
Efficacy and bleeding outcomes were similar with enoxaparin versus dabigatran 150 mg once daily (See supplemental Table  1 ). Inclusion of 14-day comparative data from RECORD2 in the analysis of enoxaparin versus rivaroxaban from published 18 and unpublished sources 13 showed a similar risk of symptomatic VTE plus all-cause mortality (1.3% versus 0.7%; OR, 2.07; 95% CI, 1.36 to 3.17) and major plus clinically relevant nonmajor bleeding (2.5% versus 3.1%; OR, 0.81; 95% CI, 0.66 to 1.01).
Deleting individual studies yielded pooled results that were not significantly different from the overall pooled estimates, although in the comparison of enoxaparin versus dabigatran there was a statistically significant reduction in symptomatic VTE plus all-cause mortality after removal of the RE-MODEL trial. A funnel plot of effect size versus study precision was fairly symmetrical, with a similar number of studies on either side of the summary treatment effect for symptomatic VTE plus all-cause mortality and the composite of major plus clinically relevant nonmajor bleeding (figure not shown). There were no important differences between 
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outcomes or heterogeneity results obtained using the fixedversus a random-effects model.
Discussion
In the present report, separate pooled analyses of phase III trials of enoxaparin versus dabigatran or enoxaparin versus rivaroxaban after hip or knee arthroplasty indicated different risk-benefit profiles. Enoxaparin had similar rates of efficacy and risk of bleeding compared with dabigatran. When compared with rivaroxaban, however, enoxaparin was associated with a significant 2-fold increase in the risk of symptomatic VTE plus all-cause mortality, equivalent to an excess of 6 events per 1000 patients treated, although there was also a significantly lower risk of major or clinically relevant nonmajor bleeding, equivalent to 6 fewer events per 1000 patients treated.
There was a discrepancy in the results of the primary trial outcome (total VTE plus all-cause mortality) in the individual trials comparing enoxaparin and dabigatran. Whereas the trials comparing enoxaparin 40 mg once daily with dabigatran showed similar efficacy outcomes, 6,7 the trial comparing enoxaparin 30 mg twice daily with dabigatran showed that enoxaparin was superior to dabigatran. 5 There were, however, no statistically significant differences in the risk of any category of bleeding between dabigatran and enoxaparin in any of the trials. In contrast, the individual trials comparing enoxaparin with rivaroxaban showed superior efficacy of rivaroxaban with regard to total VTE plus all-cause mortality, 8 -10 major VTE 8, 9 and symptomatic VTE, 9 with no significant difference in the risk of any category of bleeding with rivaroxaban compared with enoxaparin.
Significant heterogeneity was demonstrated when comparing dabigatran with enoxaparin for the pooled outcome of symptomatic VTE plus all-cause mortality. This was probably due to the imprecise estimates of treatment effect observed in the RE-MODEL trial compared with the other 2 Figure 2 . Secondary outcome analyses for enoxaparin versus dabigatran. ALT indicates alanine aminotransferase; BR, bilirubin; Hb, hemoglobin; and ULN, upper limit of normal. P value for overall effect is shown. Significant heterogeneity was seen for the outcomes: major bleeding leading to a fall in hemoglobin (Pϭ0.07, I 2 ϭ63%) and major bleeding leading to transfusion (Pϭ0.08, I 2 ϭ60%).
trials. However, other secondary efficacy outcomes, including symptomatic pulmonary embolism and major VTE plus VTE-related mortality, showed no significant heterogeneity, and we believe that the heterogeneity for symptomatic VTE plus all-cause mortality is likely due to the play of chance. The ongoing hip arthroplasty trial RE-NOVATE II should provide further clarification. 19 In contrast, rivaroxaban demonstrated significantly better efficacy, not only for the primary efficacy outcome but also for the outcome of symptomatic deep-vein thrombosis, without significant heterogeneity. However, this was balanced by a significant increase in the risk of major and clinically relevant nonmajor bleeding. Secondary bleeding outcomes including major bleeding events, bleeding leading to transfusion of at least 2 U of whole blood or packed cells, and bleeding leading to a fall in hemoglobin were also more common in patients treated with rivaroxaban, although there was a lack of statistical power to detect clinically important differences caused by the small number of events. Subgroup analysis that included RECORD2 yielded similar results for the primary efficacy and bleeding outcomes; rivaroxaban showed better efficacy compared with enoxaparin but had a higher risk of bleeding. Although the clinical development programs for rivaroxaban and dabigatran for the prevention of VTE in major joint arthroplasty have some common methodological featurestype of surgery, comparator drug, use of extended-duration of prophylaxis after hip arthroplasty, and geographical distribution-there are also important differences. In each of the individual trials, the primary outcome was the incidence of total VTE plus all-cause mortality. However, for patients treated with enoxaparin in the dabigatran trials, the rate of this primary outcome was more than 2-fold higher than that observed in the rivaroxaban trials (mean, 20.1% versus 9.5%). In part, this may be due to recognized differences in the methods used by venogram adjudication committees to assess the incidence of asymptomatic deep-vein thrombosis. 20 Additionally, there was a 7-fold proportional difference in the rate of major bleeding for patients receiving enoxaparin in trials versus dabigatran than versus rivaroxaban (mean, 1.4% versus 0.2%). This is almost certainly related to recognized differences in the definition of major bleeding. 21 In the trials comparing enoxaparin with rivaroxaban, bleeding at the surgical site, which usually accounts for 80% to 90% of bleeding events, 6, 7, 22, 23 was excluded from the definition of major bleeding, except if the event resulted in reoperation or death. However, the main driver of differences in the absolute rate of major bleeding between the 2 analyses relates to the individual categories "bleeding associated with a fall in hemoglobin of at least 20 g/L" and "bleeding requiring transfusion of 2 or more units of blood." In the enoxaparin versus dabigatran trials, enoxaparin-treated patients had 32 and 33 events, respectively, in these 2 categories. In the trials versus rivaroxaban, only 1 event in each category was reported in patients receiving enoxaparin. This substantial difference not only relates to exclusion of surgical-site bleeding in the rivaroxaban trials but also to how the fall in hemoglobin after surgery was calculated. In the dabigatran trials, the reference hemoglobin value was the preoperative baseline level, whereas in the rivaroxaban trials it was the value at the time of the first rivaroxaban dose, 6 to 8 hours after surgery. 8 Similarities between the 2 trial programs enhance our decision to present 2 separate analyses side-by-side. In view of our aim to assess clinically important efficacy and bleeding outcomes, the primary outcomes we used in this analysis differed from those employed in each of the individual trials. Each of these outcomes was largely adjudicated by the same independent committees in each of the 6 trials, thereby reducing potential bias in interobserver interpretation. The outcome of symptomatic VTE plus all-cause mortality is a relatively robust outcome and not as sensitive to variability as for the assessment of asymptomatic venographic deep-vein thrombosis. 20 Because screening for asymptomatic deep-vein thrombosis is not done in clinical practice, the most relevant benefit for the practicing physician regarding VTE prophylaxis after hip and knee arthroplasty is the prevention of symptomatic events. Indeed, the event rates for enoxaparin for comparison with dabigatran or rivaroxaban were reasonably similar (0.9% and 1.2%). For the assessment of bleeding, we used the composite end point of major plus clinically relevant nonmajor bleeding rather than the primary safety end point of "major bleeding" used in each of the trial publications. This latter outcome, which comprised mainly excessive wound hematoma and surgical-site bleeding (data not shown), was largely defined in the same way in each trial program (See supplemental Table 2 ) and contributed toward most events reported for the composite outcome (209 of 286 events [73.1%] for enoxaparin versus dabigatran, and 249 of 280 events [88.9%] for enoxaparin versus rivaroxaban), thus accounting for the effect of marked differences in the definition of major bleeding within each trial program. Despite this, there was still a 2-fold difference in the composite bleeding event rate for enoxaparin in the dabigatran trials compared with rivaroxaban trials (5.0% versus 2.5%), which again precludes direct comparisons between the 2 trial programs. Figure 4 . Secondary outcome analyses for enoxaparin versus rivaroxaban. ALT indicates alanine aminotransferase; BR, bilirubin; Hb, hemoglobin; and ULN, upper limit of normal. Probability value for overall effect is shown. Significant heterogeneity was seen for cardiovascular events after treatment discontinuation (Pϭ0.04, I 2 ϭ69%).
The safety profiles of dabigatran and rivaroxaban during treatment were similar to that of enoxaparin with respect to liver enzyme elevations and acute cardiovascular events, although the incidence of moderate transaminase elevations was significantly lower with either agent compared with enoxaparin. In addition, there was no significant increase in the rate of adverse events or wound infections with either compound compared with enoxaparin. The risk of death appeared to be lower for patients treated with enoxaparin versus dabigatran ( supplemental Tables 3 and 4) , and the overall mortality rate in the trials was generally low. Therefore, this is likely to be a chance finding because of the small number of events and the wide confidence intervals for the estimates of treatment effect. Although the large data set presented for safety and adverse event data with dabigatran and rivaroxaban are reassuring that there does not appear to be any major differences between these new anticoagulants and enoxaparin, because of the rarity of many of the events, much larger postmarketing data sets need to accrue before any definitive statements can be made.
We acknowledge some limitations in our analyses. First, as explained, our results do not permit a direct comparison of dabigatran with rivaroxaban. The aim of our analysis was to present data for the 2 analyses side-by-side using similar end points, which would allow clinicians to make informed and objective assessment of the 2 new drug treatments compared with enoxaparin, a parenteral anticoagulant with a wellestablished efficacy and safety profile. Second, our analysis used study-level data rather than patient-level data. Although separate analyses based on individual-patient data would have been beneficial to assess the data with time-to-event methodology and explore baseline patient characteristics that might predict important clinical outcomes, the logistic challenges with obtaining multiple data sets meant that is was not possible to perform this type of analysis. Third, with only 3 trials within each meta-analysis, we were not able to fully explore individual subgroups according to the dose of enoxaparin (40 mg once daily versus 30 mg twice daily) or type of arthroplasty (hip versus knee), in which clinically important benefits might have been observed. Despite the relatively small number of trials included in our meta-analyses (3 in each comparison), each of the individual trials were substantially larger than previous randomized, controlled trials conducted in this surgical setting. 3 Other than the RE-NOVATE II study, 19 it is unlikely that any further randomized trials will be conducted with these agents. Therefore, data from this meta-analysis represents the best estimates of the efficacy and safety of enoxaparin compared with dabigatran or rivaroxaban in patients undergoing hip or knee arthroplasty. Forth, by nature of the trial design used in each study, patients with impaired renal function and the very elderly were excluded and thus general conclusions drawn from these analyses only pertain to the highly selected individuals and caution is needed with extrapolation to the general population. Finally, meta-analysis remains retrospective research that is subject to the methodological deficiencies of the included studies. However, we minimized the likelihood of bias by developing a detailed protocol before commencing this study, performing a meticulous and exhaustive search for both published and unpublished trial data, and using explicit methodology for study selection, data extraction, and data analysis.
Our findings may have important implications for the choice of prophylactic agent in major joint arthroplasty. Balancing the risks of bleeding with the risks of thromboembolic events is commonly performed by surgeons performing lower-limb joint arthroplasty, and choice of prophylactic therapy is often determined on an individual basis. Because both dabigatran and rivaroxaban are administered orally and therefore are more convenient than parenterally administered anticoagulants, particularly for out-of-hospital prophylaxis, either agent may be an attractive alternative for patients undergoing total hip or knee arthroplasty.
